Tumour-associated directed immunity in prostatic cancer as evaluated by tube antigen-induced leukocyte adherence inhibition: Effect of seminal plasma on cytophilic antibody ('arming' factor) in the sera of patients with prostatic cancer

R. A. Bhatti, R. J. Ablin, E. Totonchi

Research output: Contribution to journalArticlepeer-review

Abstract

In an initial inquiry of the existence of the prostate as an immunologically privileged site due to immunosuppressive properties of its secretory milieu as being contributory to the high incidence of occult prostatic carcinoma and wide variation in the age of onset of clinical disease, normal human seminal plasma was observed to suppress tumour-associated directed immunity in patients with prostatic cancer. In extending these initial observations, the effect of HuSP1 on a disease related activating or 'arming' factor in the sera of prostatic cancer patients has been evaluated.

Original languageEnglish (US)
Pages (from-to)372
Number of pages1
JournalIRCS Medical Science
Volume7
Issue number7
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Tumour-associated directed immunity in prostatic cancer as evaluated by tube antigen-induced leukocyte adherence inhibition: Effect of seminal plasma on cytophilic antibody ('arming' factor) in the sera of patients with prostatic cancer'. Together they form a unique fingerprint.

Cite this